6626-40-0

Basic information

• Product Name: 7,10-dichloro-2-methoxybenzo[b]-1,5-naphthyridine
• Synonyms: 7,10-dichloro-2-methoxybenzo[b]-1,5-naphthyridine
• CAS NO: 6626-40-0
• Molecular Formula: C₁₃H₈Cl₂N₂O
• Molecular Weight: 279.12142
• EINECS: 229-588-9
• Mol File: 6626-40-0.mol
• Article Data: 9

Chemical Properties

• Melting Point: 186-187 °C
• Boiling Point: 434 °C at 760 mmHg
• Flash Point: 216.3 °C
• Appearance: /
• Density: 1.453 g/cm³
• Vapor Pressure: 2.48E-07mmHg at 25°C
• Refractive Index: 1.704
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Chloroform (Sparingly), DMSO (Slightly, Heated), Methanol (Slightly, Heated)
• PKA: 0.49±0.40(Predicted)
• CAS DataBase Reference: 7,10-dichloro-2-methoxybenzo[b]-1,5-naphthyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 7,10-dichloro-2-methoxybenzo[b]-1,5-naphthyridine(6626-40-0)
• EPA Substance Registry System: 7,10-dichloro-2-methoxybenzo[b]-1,5-naphthyridine(6626-40-0)

Safety Data

• Hazardous Substances Data: 6626-40-0(Hazardous Substances Data)

Usage

Uses

7,10-Dichloro-2-methoxybenzo[b][1,5]naphthyridine is used in the preparation of pyronaridine.

InChI:InChI=1/C13H8Cl2N2O/c1-18-11-5-4-9-13(17-11)12(15)8-3-2-7(14)6-10(8)16-9/h2-6H,1H3

Upstream product

• 6628-77-9 6-methoxy-pyridin-3-ylamine 
• 50-84-0 2,4 dichlorobenzoic acid 
• 6626-07-9 4-chloro-2-(6-methoxy-pyridin-3-yl-amino)-benzoic acid 
• 504-29-0 2-aminopyridine 
• 4214-76-0 5-nitro-pyridin-2-ylamine 
• 5418-51-9 5-nitro-2-hydroxypyridine 
• 4548-45-2 2-chloro-5-nitropyridine 
• 5446-92-4 2-methoxy-5-nitropyridine 

Downstream Products

• 152235-94-4 2-methoxy-7-chloro-10-phenoxypyrido<3,2-b>quinoline 
• 1269526-49-9 7-chloro-2-methoxy-10-(4-(4'-chlorobenzylidene)aminophenyl)aminobenzo[b][1,5]naphthyridine 
• 1269526-50-2 7-chloro-2-methoxy-10-(4-(4'-bromobenzylidene)aminophenyl)aminobenzo[b][1,5]naphthyridine 
• 1269526-51-3 7-chloro-2-methoxy-10-(4-(4'-hydroxylbenzylidene)aminophenyl)amino-benzo[b][1,5]naphthyridine 
• 1269526-52-4 7-chloro-2-methoxy-10-(4-(4'-methoxylbenzylidene)aminophenyl)aminobenzo[b][1,5]naphthyridine 
• 1269526-53-5 7-chloro-2-methoxy-10-(4-(2',4'-dimethylbenzylidene)aminophenyl)aminobenzo[b][1,5]naphthyridine 
• 1269526-54-6 7-chloro-2-methoxy-10-(4-(2',3'-dimethylbenzylidene)aminophenyl)aminobenzo[b][1,5]naphthyridine 
• 1269526-55-7 7-chloro-2-methoxy-10-(4-(2',4'-dihydroxylbenzylidene)aminophenyl)aminobenzo[b][1,5]naphthyridine 
• 1269526-56-8 7-chloro-2-methoxy-10-(4-(2',4'-methoxylbenzylidene)aminophenyl)aminobenzo[b][1,5]naphthyrdine 
• 1269526-57-9 7-chloro-2-methoxy-10-(4-(2',4'-dichlorobenzylidene)aminophenyl)aminobenzo[b][1,5]naphthyrdine 
• 1269526-58-0 7-chloro-2-methoxy-10-(4-(2'-pyridylidene)aminophenyl)aminobenzo[b][1,5]naphthyridine 
• 1269526-59-1 7-chloro-2-methoxy-10-(4-(3'-pyridylidene)aminophenyl)aminobenzo[b][1,5]-naphthyridine 
• 1269526-46-6 7-chloro-2-methoxy-10-(4-aminophenyl)-aminobenzo[b][1,5]naphthyridine 
• 1269526-47-7 7-chloro-2-methoxy-10-(4-benzylideneaminophenyl)aminobenzo[b][1,5 ]naphthyridine 

Relevant articles and documents

ACRIDIN-9-YL-AMINE, QUINOLIN-9-YL-AMINE, 1 -AMINO-9H-THIOXANTHENE-9-ONE AND BENZO[B][1,5]NAPHTHYRI DIN-10-YL-AMINE DERIVATIVES AS AUTOPHAGY INHIBITORS FOR TREATING CANCER

This disclosure provides a cridin-9-yl-amine, quinolin-9-yl-amine, 1- amino-9H-thioxanthene-9-one and benzo[b][l,5]naphthyridin-10- yl-amine derivatives and structurally related compounds for use as autophagy inhibitors for treating cancer. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 77 to 155; examples 1 to 22; compound A; compounds 1 to 21; tables 1 to 3).

Design, synthesis and biological evaluation of novel phthalazinone acridine derivatives as dual PARP and Topo inhibitors for potential anticancer agents

In this study, we designed and synthesized a series of phthalazinone acridine derivatives as dual PARP and Topo inhibitors. MTT assays indicated that most of the compounds significantly inhibited multiple cancer cells proliferation. In addition, all the compounds displayed Topo II inhibition activity at 10 mol/L, and also possessed good PARP-1 inhibitory activities. Subsequent mechanistic studies showed that compound 9a induced remarkable apoptosis and caused prominent S cell cycle arrest in HCT116 cells. Our study suggested that 9a inhibiting Topo and PARP concurrently can be a potential lead compound for cancer therapy.

Synthesis and biological research of novel azaacridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors

DNA and DNA-related enzymes are one of the most effective and common used intracellular anticancer targets in clinic and laboratory studies, however, most of DNA-targeting drugs suffered from toxic side effects. Development of new molecules with good antitumor activity and low side effects is important. Based on computer aided design and our previous studies, a series of novel azaacridine derivatives were synthesized as DNA and topoisomerases binding agents, among which compound 9 displayed the best antiproliferative activity with an IC50 value of 0.57?μM against U937 cells, which was slightly better than m-AMSA. In addition, compound 9 displayed low cytotoxicity against human normal liver cells (QSG-7701), the IC50 of which was more than 3 times lower than m-AMSA. Later study indicated that all the compounds displayed topoisomerases II inhibition activity at 50?μM. The representative compound 9 could bind with DNA and induce U937 apoptosis through the exogenous pathway.